{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:52:52Z","timestamp":1768891972502,"version":"3.49.0"},"reference-count":40,"publisher":"Impact Journals, LLC","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,11,17]]},"DOI":"10.18632\/oncotarget.5508","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T03:46:00Z","timestamp":1444016760000},"page":"39184-39195","source":"Crossref","is-referenced-by-count":12,"title":["Effects of interferons and double-stranded RNA on human prostate cancer cell apoptosis"],"prefix":"10.18632","volume":"6","author":[{"given":"Haiyan","family":"Tan","sequence":"first","affiliation":[{"name":"Clinical Chemistry Program, Department of Chemistry, Cleveland State University, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Zeng","sequence":"additional","affiliation":[{"name":"Clinical Chemistry Program, Department of Chemistry, Cleveland State University, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junbo","family":"Xie","sequence":"additional","affiliation":[{"name":"College of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah J.","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Clinical Chemistry Program, Department of Chemistry, Cleveland State University, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Song","sequence":"additional","affiliation":[{"name":"College of basic medical sciences, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Clinical Chemistry Program, Department of Chemistry, Cleveland State University, Cleveland, OH, USA"},{"name":"Center for Gene Regulation in Health and Diseases, Cleveland State University, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Jin","sequence":"additional","affiliation":[{"name":"Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2015,10,1]]},"reference":[{"key":"1","unstructured":"American cancer association. Overview: prostate cancer. 2014."},{"key":"2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2006.05.017","article-title":"Management of the spectrum of hormone refractory prostate cancer","volume":"50","author":"Clarke","year":"2006","journal-title":"European urology"},{"key":"3","first-page":"1851","article-title":"Preclinical profile of cabazitaxel","volume":"8","author":"Gupta","year":"2014","journal-title":"Drug design, development and therapy"},{"key":"4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.urolonc.2009.12.023","article-title":"Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer","volume":"29","author":"Nanus","year":"2011","journal-title":"Urologic oncology"},{"key":"5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/pros.22830","article-title":"The role of the SHH gene in prostate cancer cell resistance to paclitaxel","volume":"74","author":"Malecki","year":"2014","journal-title":"The Prostate"},{"key":"6","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/jcb.24464","article-title":"Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer","volume":"114","author":"Mooney","year":"2013","journal-title":"Journal of cellular biochemistry"},{"key":"7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Stark","year":"2007","journal-title":"Nature reviews Drug discovery"},{"key":"8","first-page":"412","article-title":"Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design","volume":"5","author":"Ranasinghe","year":"2014","journal-title":"Frontiers in immunology"},{"key":"9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clinical microbiology reviews"},{"key":"10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminoncol.2014.02.002","article-title":"Interferons and their stimulated genes in the tumor microenvironment","volume":"41","author":"Stark","year":"2014","journal-title":"Seminars in oncology"},{"key":"11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1634\/theoncologist.2-4-254","article-title":"New Advances in Interferon Therapy of Cancer","volume":"2","author":"Schwartz","year":"1997","journal-title":"The oncologist"},{"key":"12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/scbi.2000.0315","article-title":"Second-generation interferons for cancer: clinical targets","volume":"10","author":"Peereboom","year":"2000","journal-title":"Seminars in cancer biology"},{"key":"13","first-page":"3","article-title":"A perspective on the clinical effectiveness and tolerance of interferon-alpha","volume":"25","author":"Parkinson","year":"1998","journal-title":"Seminars in oncology"},{"key":"14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood.V100.2.647","article-title":"Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion","volume":"100","author":"Cawley","year":"2002","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/jir.2006.0120","article-title":"Recombinant human IFN-beta affects androgen receptor level, neuroendocrine differentiation, cell adhesion, and motility in prostate cancer cells","volume":"27","author":"Sica","year":"2007","journal-title":"Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research"},{"key":"16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.lfs.2007.05.028","article-title":"Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth","volume":"81","author":"Huang","year":"2007","journal-title":"Life sciences"},{"key":"17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/jir.1986.6.713","article-title":"Toxicities of human recombinant interferon-alpha 2 in patients with advanced prostate carcinoma","volume":"6","author":"Boros","year":"1986","journal-title":"Journal of interferon research"},{"key":"18","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/1097-0142(19921101)70:9<2310::AID-CNCR2820700916>3.0.CO;2-4","article-title":"A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer","volume":"70","author":"Burch","year":"1992","journal-title":"Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Borden","year":"2003","journal-title":"Apoptosis: an international journal on programmed cell death"},{"key":"20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4049\/jimmunol.169.2.847","article-title":"IFN-beta pretreatment sensitizes human melanoma cells to TRAIL\/Apo2 ligand-induced apoptosis","volume":"169","author":"Borden","year":"2002","journal-title":"Journal of immunology"},{"key":"21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1089\/107999003772084860","article-title":"Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2","volume":"23","author":"Borden","year":"2003","journal-title":"Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research"},{"key":"22","doi-asserted-by":"crossref","first-page":"24965","DOI":"10.1074\/jbc.M101161200","article-title":"Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells","volume":"276","author":"Lindner","year":"2001","journal-title":"The Journal of biological chemistry"},{"key":"23","first-page":"5720","article-title":"Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel","volume":"62","author":"Killion","year":"2002","journal-title":"Cancer research"},{"key":"24","first-page":"41","article-title":"Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer","volume":"7","author":"Mohammad","year":"2008","journal-title":"Journal of experimental therapeutics & oncology"},{"key":"25","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1158\/0008-5472.CAN-04-4316","article-title":"IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression","volume":"65","author":"Schreiber","year":"2005","journal-title":"Cancer research"},{"key":"26","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/carcin\/bgn149","article-title":"Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism","volume":"29","author":"Riccioli","year":"2008","journal-title":"Carcinogenesis"},{"key":"27","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1093\/emboj\/16.21.6355","article-title":"Interferon action and apoptosis are defective in mice devoid of 2\u2032,5\u2032-oligoadenylate-dependent RNase, L","volume":"16","author":"Silverman","year":"1997","journal-title":"The EMBO journal"},{"key":"28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.cdd.4400794","article-title":"DAP-kinase: from functional gene cloning to establishment of its role in apoptosis and cancer","volume":"8","author":"Kimchi","year":"2001","journal-title":"Cell death and differentiation"},{"key":"29","doi-asserted-by":"crossref","first-page":"14782","DOI":"10.1073\/pnas.1417253111","article-title":"Activation of mitochondrial protease OMA1 by Bax and Bak promotes cytochrome c release during apoptosis","volume":"111","author":"Wang","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"30","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/374736a0","article-title":"Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak","volume":"374","author":"Barr","year":"1995","journal-title":"Nature"},{"key":"31","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-06-1432","article-title":"Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and\/or metastatic renal cell carcinoma or malignant melanoma","volume":"13","author":"Robert","year":"2007","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"32","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Small","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2002.20.2.364","article-title":"Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer","volume":"20","author":"Lippman","year":"2002","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"34","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1525-1438.2006.00622.x","article-title":"Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I\/II study","volume":"16","author":"Mueller-Holzner","year":"2006","journal-title":"International journal of gynecological cancer: official journal of the International Gynecological Cancer Society"},{"key":"35","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.1158\/0008-5472.CAN-04-2226","article-title":"HPC1\/RNASEL mediates apoptosis of prostate cancer cells treated with 2\u2032,5\u2032-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand","volume":"64","author":"Silverman","year":"2004","journal-title":"Cancer research"},{"key":"36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.bbrc.2012.05.056","article-title":"Combined anti-tumor effects of IFN-alpha and sorafenib on hepatocellular carcinomaand","volume":"422","author":"Gu","year":"2012","journal-title":"Biochemical and biophysical research communications"},{"key":"37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s12272-010-0214-5","article-title":"Interferon-gamma enhances the apoptosis of macrophages under trophic stress through activation of p53 and the JAK1 pathway","volume":"33","author":"Pyo","year":"2010","journal-title":"Archives of pharmacal research"},{"key":"38","doi-asserted-by":"crossref","first-page":"39632","DOI":"10.1074\/jbc.M111.253591","article-title":"Cytokines tumor necrosis factor-alpha and interferon-gamma induce pancreatic beta-cell apoptosis through STAT1-mediated Bim protein activation","volume":"286","author":"Gurzov","year":"2011","journal-title":"The Journal of biological chemistry"},{"key":"39","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1074\/jbc.M114.601625","article-title":"Transfected poly(I:C) activates different dsRNA receptors, leading to apoptosis or immunoadjuvant response in androgen-independent prostate cancer cells","volume":"290","author":"Riccioli","year":"2015","journal-title":"The Journal of biological chemistry"},{"key":"40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/jcmm.12379","article-title":"TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth","volume":"19","author":"Riccioli","year":"2015","journal-title":"Journal of cellular and molecular medicine"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T17:38:43Z","timestamp":1589391523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,1]]},"references-count":40,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2015,11,17]]}},"alternative-id":["5508","26452032"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5508","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,1]]}}}